Caribou’s Phase I CAR-T Data In Lymphoma Show Improvement In Durability

 
• By Alaric DeArment

CB-010 still has a way to go, but data from 16 patients in the ANTLER trial showed a higher six-month CR rate than when the company reported data for five patients at EHA in 2022.

Caribou announced updated Phase I data from the ANTLER trial of allogeneic CAR-T CB-010 in non-Hodgkin lymphomas • Source: Shutterstock

More from Clinical Trials

More from R&D